This session will take place on 10th September at 10:00 CEST.
Chairperson(s): F. Bandello ITALY & C. Creuzot-Garcher FRANCE
Chairperson
10:00 Welcome and introduction
A. Hunt AUSTRALIA
10:01 Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
D. Barthelmes SWITZERLAND
10:05 Twelve-Month Treatment Outcomes of Macular Edema Following Central Retinal Vein Occlusion using Aflibercept or Ranibizumab in Routine Clinical Practice – Data from the Fight Retinal Blindness! Project
All Faculty
10:09 Discussion
R. Tadayoni FRANCE
10:15 Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema: One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
J. Cunha-Vaz PORTUGAL
10:19 OCT-A metrics monitor severity progression of Diabetic Retinopathy – 3-year longitudinal study
All Faculty
10:23 Discussion
T. van Bergen BELGIUM
10:29 Targeting plasma kallikrein with a novel bicyclic peptide inhibitor (THR-149) reduces retinal inflammation and reactive gliosis in a diabetic rat model
F. Bandello ITALY
10:33 A Novel Bicyclic Peptide Inhibitor of Plasma Kallikrein, THR-149, for the Treatment of Diabetic Macular Edema (DME): Clinical and Pre-Clinical Evidence
All Faculty
10:37 Discussion
10:45 End of Session
The programme schedule may be subject to change. Please refer to the interactive programme for the most up to date details.
